Effect of Ephedra Herb on Erlotinib Resistance in c-Met-Overexpressing Non-Small-Cell Lung Cancer Cell Line, H1993, through Promotion of Endocytosis and Degradation of c-Met

Figure 2

The effect of a combination of EHE and erlotinib or a combination of SU11274 and erlotinib on growth of H1993 cells in vitro. H1993 cells (2 × 10³ cells) were suspended in 100 μl of 10% FCS-RPMI 1640 medium in a 96-well plate. After 24 (h), the medium was removed and to each well 100 μl of 10% FCS-RPMI 1640 medium was added: (a) with or without 2.5, 5, and 10 µM erlotinib, 100, 200, and 400 µg/ml EHE, or a combination of erlotinib and EHE; or (b) with or without 1.25 and 2.5 µM SU11274 or a combination of erlotinib and SU11274. After 6 days, the cell viability was determined by Cell Counting Kit-8. Relative viability is expressed as absorbance of cells in 10% FCS-medium with the added test drug/absorbance of cells in 10% FCS-medium. Each error bar represents the average (n = 4) ± S.D. Data were analyzed by 2-way ANOVA (A : DF = 3, F(3, 47) = 828.5, and ; B : DF = 3, F(3, 34) = 266.3, and ). Significant differences were determined by Dunnett’s test; , , and vs. the erlotinib group.

(a)

(b)